Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study

Fasting and post-prandial glucagon like peptide 1 and oral contraception in polycystic ovary syndrome

(2014) Kadriye Aydin et al.   CLINICAL ENDOCRINOLOGY

Phosphodiesterase 4 Inhibition as a Potential New Therapeutic Target in Obese Women With Polycystic Ovary Syndrome

(2014) Mojca Jensterle et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease

(2013) H. Kahal et al.   CLINICAL ENDOCRINOLOGY

Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin

(2013) Mojca Jensterle Sever et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline

(2013) Richard S. Legro et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Lifestyle Modification Programs in Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis

(2013) Juan Pablo Domecq et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Standards of Medical Care in Diabetes--2013

(2012)   DIABETES CARE

The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice

(2012) S. Vollert et al.   DIABETOLOGIA

Effect of the Phosphodiesterase 4 Inhibitor Roflumilast on Glucose Metabolism in Patients with Treatment-Naive, Newly Diagnosed Type 2 Diabetes Mellitus

(2012) E. F. M. Wouters et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The roles of cyclic nucleotide phosphodiesterases (PDEs) in steroidogenesis

(2011) Li-Chun Lisa Tsai et al.   CURRENT OPINION IN PHARMACOLOGY

Phosphodiesterases in endocrine physiology and disease

(2011) Delphine Vezzosi et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

(2011) A Astrup et al.   INTERNATIONAL JOURNAL OF OBESITY

Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice

(2010) A. Maida et al.   DIABETOLOGIA

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials

(2009) Leonardo M Fabbri et al.   LANCET

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

(2009) Peter MA Calverley et al.   LANCET

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis

(2008) A.E. Nieuwenhuis-Ruifrok et al.   HUMAN REPRODUCTION UPDATE

Comparison of Single and Combined Treatment with Exenatide and Metformin on Menstrual Cyclicity in Overweight Women with Polycystic Ovary Syndrome

(2008) Karen Elkind-Hirsch et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Impact of Obesity on the Risk for Polycystic Ovary Syndrome

(2007) Bulent O. Yildiz et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM